<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14933">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02912468</url>
  </required_header>
  <id_info>
    <org_study_id>EFC14146</org_study_id>
    <secondary_id>2015-003101-42</secondary_id>
    <secondary_id>U1111-1178-5390</secondary_id>
    <nct_id>NCT02912468</nct_id>
  </id_info>
  <brief_title>A Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps</brief_title>
  <official_title>A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone
      furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and
      endoscopic nasal polyp score (NPS) in patients with bilateral nasal polyposis (NP). In
      addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses
      will be also a co-primary objective.

      Secondary Objectives:

        -  To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).

        -  To evaluate the efficacy of dupilumab in improving sense of smell.

        -  To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses
           (Primary objective for Japan).

        -  To evaluate ability of dupilumab in reducing proportion of patients requiring treatment
           with oral corticosteroids or NP surgery.

        -  To evaluate the effect of dupilumab on patient reported outcomes and health related
           quality of life outcome by sinonasal outcome test-22 (SNOT-22).

        -  To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and
           co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated
           respiratory disease [NERD]).

        -  To evaluate residual effect in follow up.

        -  To evaluate the safety of dupilumab in patients with bilateral NP.

        -  To evaluate functional dupilumab concentrations (systemic exposure) and incidence of
           treatment-emergent anti-drug antibodies (ADA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per patient is expected to be up to 52 weeks that will consist of a
      4-week run-in period, 24-week treatment period, and a 24-week posttreatment period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in NC symptom severity score based on the patient daily morning assessment</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in NPS as assessed by nasal endoscopy</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total symptom score</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in University of Pennsylvania Smell Identification Test</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in severity of decreased/loss of smell as assessed by patient daily</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sinonasal outcome test-22 (SNOT-22)</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients during study treatment receiving oral corticosteroid for NP and/or planned to undergo surgery for nasal polyps</measure>
    <time_frame>At Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Dupilumab (Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose of dupilumab will be administered subcutaneously (SC) every 2 weeks (q2w) up to Week 24. Patients will use MFNS daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Arm B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A matching placebo will be administered subcutaneously (SC) every 2 weeks (q2w) up to Week 24. Patients will use MFNS daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab SAR231893 (REGN668)</intervention_name>
    <description>Pharmaceutical form: Solution
Route of administration: Subcutaneous</description>
    <arm_group_label>Dupilumab (Arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: Solution
Route of administration: Subcutaneous</description>
    <arm_group_label>Placebo (Arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate nasal spray</intervention_name>
    <description>Pharmaceutical form: Suspension
Route of administration: Intranasal</description>
    <arm_group_label>Dupilumab (Arm A)</arm_group_label>
    <arm_group_label>Placebo (Arm B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with bilateral sinonasal polyposis that despite prior treatment with
             systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical
             contraindication / intolerance to SCS, and/or had prior surgery for NP at the
             screening visit, have:

          -  An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum
             score of 2 in each nasal cavity).

          -  Ongoing symptoms (for at least 8 weeks prior to V1) of nasal
             congestion/blockage/obstruction with moderate or severe symptom severity (score 2 or
             3) at V1 and a weekly average severity of greater than 1 at the time of randomization
             (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).

          -  Signed written informed consent.

        Exclusion criteria:

          -  Patients &lt;18 years of age.

          -  Patient who has previously been treated in dupilumab studies.

          -  Patient who has taken:

               -  Biologic therapy/systemic immunosuppressant to treat inflammatory disease or
                  autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease,
                  primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis,
                  etc.) within 2 months before V1 or 5 half-lives, whichever is longer.

               -  Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6
                  months before V1 if the half-life is unknown.

               -  Anti-immunoglobulin E (IgE) therapy (omalizumab) within 130 days prior to V1.

               -  Leukotriene antagonists/modifiers unless patient is on a continuous treatment
                  for at least 30 days prior to V1.

          -  Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin
             therapy or change its dose during the run-in period or the randomized treatment
             period.

          -  Patients who have undergone any intranasal and/or sinus surgery (including
             polypectomy) within 6 months prior to V1.

          -  Patients who have had a sinonasal or sinus surgery changing the lateral wall
             structure of the nose making impossible the evaluation of NPS.

          -  Patients with conditions/concomitant diseases making them nonevaluable at V1 or for
             the primary efficacy endpoint such as:

               -  Antrochoanal polyps.

               -  Nasal septal deviation that would occlude at least one nostril.

               -  Acute sinusitis, nasal infection or upper respiratory infection.

               -  Ongoing rhinitis medicamentosa.

               -  Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with
                  polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome
                  or other dyskinetic ciliary syndromes, concomitant cystic fibrosis.

               -  Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.

          -  Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood
             boil etc).

          -  Patients with forced expiratory volume in 1 second (FEV1) 50% or less (of predicted
             normal).

          -  Patients receiving concomitant treatment prohibited in the study.

          -  Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.

          -  History of human immunodeficiency virus (HIV) infection or positive HIV serology at
             screening.

          -  Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the
             screening visit.

          -  Active chronic or acute infection requiring systemic treatment within 2 weeks before
             the baseline visit.

          -  Known or suspected history of immunosuppression.

          -  Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed
             during the study.

          -  Women unwilling to use adequate birth control, if of reproductive potential and
             sexually active.

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8400009</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400004</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400014</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400002</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400016</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400022</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400021</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400019</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400020</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1000003</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1000001</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030002</name>
      <address>
        <city>Pardubice</city>
        <zip>53203</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2030004</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500005</name>
      <address>
        <city>La Roche Sur Yon Cedex 9</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500003</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500001</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500006</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500004</name>
      <address>
        <city>Vandoeuvre-Les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760001</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3480006</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3480003</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3480005</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3480002</name>
      <address>
        <city>PÃ©cs</city>
        <zip>7621</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3480001</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800004</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800006</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800001</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800003</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5280001</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6160002</name>
      <address>
        <city>Katowice</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6160001</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6160003</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430003</name>
      <address>
        <city>Moscow</city>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430007</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430002</name>
      <address>
        <city>St-Petersburg</city>
        <zip>190013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8040002</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8040004</name>
      <address>
        <city>Kharkiv</city>
        <zip>61166</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8040006</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8040001</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8040008</name>
      <address>
        <city>Ternopil</city>
        <zip>46000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260001</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260002</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260007</name>
      <address>
        <city>Great Yarmouth</city>
        <zip>NR31 6LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260004</name>
      <address>
        <city>Stockport</city>
        <zip>SK2 7JE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260005</name>
      <address>
        <city>Wigan</city>
        <zip>WN1 2NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>September 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
